References

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

10.1016/s2352-3018(22)00291-0 · 2023 · External reference

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

10.1016/s2352-3018(23)00113-3 · 2023 · External reference

Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women

10.1056/nejmoa2407001 · 2024 · External reference

Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons

10.1056/nejmoa2411858 · 2025 · External reference

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, noninferiority trial

10.1016/s0140-6736(17)31917-7 · 2017 · External reference

Severe lenacapavir injection site nodule

10.1097/qad.0000000000004271 · 2025 · External reference

Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers

10.1111/bcp.14977 · 2022 · External reference

Benign cutaneous and subcutaneous lesions on FDG-PET/CT

10.1053/j.semnuclmed.2017.02.007 · 2017 · External reference

Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT

10.1053/j.semnuclmed.2007.01.001 · 2007 · External reference

Cutaneous and subcutaneous imaging on FDG-PET: benign and malignant findings

10.1097/rlu.0b013e3181b53845 · 2009 · External reference